News Releases

May 02, 2023 Pulmonx Reports First Quarter 2023 Financial Results
REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023.
Apr 25, 2023 Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference
REDWOOD CITY, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2023 Health Care Conference in Las Vegas
Apr 18, 2023 Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 18, 2023-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May
Feb 22, 2023 Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results
REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022.
Feb 16, 2023 Pulmonx to Present at the Citi 2023 Healthcare Conference
REDWOOD CITY, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2023 Healthcare Conference in New York on
Feb 08, 2023 Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading
Print Page
Email Alerts
Contact IR
RSS Feeds